228 completed, 57 unknown, 18 recruiting, 12 terminated. 92 Phase 4, 68 Phase 1, 64 Phase 3, 57 Not applicable, 56 Phase 2.
Follow Clarithromycin: new trials by email Literature Review of Clarithromycin trials Research Report on Clarithromycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours), Ceftriaxone for Injection, Amoxicillin - Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection | Phase 2 | Not yet recruiting | The University of Queensland | 300 | 2027-04-01 | 2026-03-20 |
| Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects JP-1366 20 mg, Lansoprazole 30 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg, Lansoprazole 30mg, JP-1366 20 mg Placebo, Clarithromycin 500mg, Amoxicillin 1000mg - H. Pylori Eradication Therapy | Phase 3 | Not yet recruiting | Onconic Therapeutics Inc. | 414 | 2026-11-01 | 2026-10-15 |
| CLARITHROMYCIN TO PREVENT SECONDARY INFECTIONS IN PATIENTS WITH SEPSIS FOLLOWING LOWER RESPIRATORY TRACT INFECTIONS: THE CLASSIFY TRIAL Placebo, clarithromycin - Sepsis | Phase 3 | Recruiting | Hellenic Institute for the Study of Sepsis | 252 | 2026-09-16 | 2026-11-03 |
| A Combination of Antibiotics to Decrease Neonatal Morbidity and Mortality for Previable Threatened Labor Combination of antibiotics, Emergency cerclage, Vaginal progesterone - Previable Labour With Intact Membranes | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 350 | 2026-09-01 | 2026-05-01 |
| Safety of Vonoprazan-Amoxicillin Dual Therapy Versus Concomitant Quadruple Therapy for H. Pylori Eradication Vonoprazan (Reference), Amoxicillin, Metronidazole - HELICOBACTER PYLORI INFECTIONS | Phase 4 | Recruiting | Ignacio Moratorio | 100 | 2026-08-05 | 2026-11-09 |
| Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet RSS0343 Tablet; Rifampicin Capsules, RSS0343 Tablet; Clarithromycin Tablets - Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease | Phase 1 | Not yet recruiting | Reistone Biopharma Company Limited | 40 | 2026-07-01 | 2026-07-10 |
| Enhanced Treatment Strategy for Disseminated MAC Infection in HIV Patients: A Randomized Controlled Trial Standard Triple Therapy, Experimental: Standard Triple Therapy Plus Fluoroquinolone - Opportunistic Infections, HIV Related, Disseminated Mycobacterium Avium Complex Infection | Not applicable | Not yet recruiting | Shanghai Public Health Clinical Center | 124 | 2026-04-30 | 2026-05-13 |
| Simplified Dual Regimen Guided by Fecal Clarithromycin Resistance Gene Detection for First-line H. Pylori Eradication Vonoprazan 20 mg twice daily + clarithromycin 500 mg twice daily for 14 days - Helicobacter Pylori Infection | Not applicable | Recruiting | Peking University First Hospital | 70 | 2026-04-25 | 2026-04-30 |
| Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection Vonoparazan, Vitamin D, Probiotic - HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection | Phase 2 | Recruiting | Tanta University | 132 | 2026-02-15 | 2026-09-09 |
| Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection zinc sulfate, Vonoprazan + amoxicillin + clarithromycin, proton pump inhibitor + amoxicillin - HELICOBACTER PYLORI INFECTIONS | Phase 3 | Recruiting | Tanta University | 88 | 2026-02-01 | 2026-09-09 |
| Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC SKB264, Clarithromycin - Ovarian Epithelial Cancer | Phase 2 | Active not recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 20 | 2026-01-16 | 2026-06-01 |
| Clinical Trial to Evaluate the Efficacy of Probit-Based Triple Therapy for Helicobacter Pylori Eradication This study aims to evaluate the efficacy and safety of a 14-day triple therapy regimen consisting of Zastaprazan 20 mg, clarithromycin, and amoxicillin for the eradication of Helicobacter pylori. - Helicobacter Infection | Phase 4 | Not yet recruiting | Samsung Medical Center | 103 | 2025-12-01 | 2025-08-14 |
| Comparison of Two Treatment Regimens of Helicobacter Pylori Infection Clarithromycin, Levofloxacin - Helicobacter Pylori Infection | Phase 4 | Not yet recruiting | Rehman Medical Institute - RMI | 156 | 2025-12-01 | 2025-06-15 |
| Drug Interaction Study on Linaprazan Glurate Capsules Linaprazan Glurate Capsules, Bismuth Potassium Citrate Capsules, Amoxicillin Capsules - Healthy Volunteers, Patients | Phase 1 | Completed | Jiangsu Sinorda Biomedicine Co., Ltd | 56 | 2025-09-08 | 2026-01-06 |
| Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma Esomeprazole, Bismuth tripotassium dicitrate, Tetracycline, and Metronidazole - MALT Lymphoma of Stomach | Phase 2 | Not yet recruiting | National Taiwan University Hospital | 40 | 2025-09-01 | 2025-08-27 |
| Tailored Vs. Empirical Helicobacter Pylori Infection Treatment Clarithromycin (mutations in the 23S rRNA gene, A2134G, A2142G and A2142C mutations) and levofloxacin resistance (mutations in the gyrA gene) PCR test, Empirically H. pylori eradication treatment with bismuth quadruple therapy (Pylera®), PPI, amoxicillin 1 g and clarithromycin 500 mg, twice daily, for 10 days - Helicobacter Pylori Infection | Phase 4 | Not yet recruiting | Manuel Coelho da Rocha | 160 | 2025-09-01 | 2024-12-20 |
| Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects HRS-5965 Capsules, Clopidogrel, Clarithromycin - Complement Mediated Glomerular Diseases, Hemolytic Anemia | Phase 1 | Completed | Chengdu Suncadia Medicine Co., Ltd. | 36 | 2025-07-08 | 2025-08-20 |
| Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection Clarithromycin 500 mg, Amoxicillin 1 g, Omeprazole 40 mg - H Pylori | Phase 4 | Not yet recruiting | Rehman Medical Institute - RMI | 128 | 2025-07-01 | 2025-06-27 |
| The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection Lansoprazole, amoxicillin, clarithromycin - Helicobacter Pylori Infection | Phase 3 | Not yet recruiting | Assiut University | 70 | 2025-06-01 | 2025-05-09 |
| Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial Vonoprazan, Tetracycline 500mg tid, Minocycline - Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer | Phase 4 | Recruiting | Yongquan Shi | 400 | 2025-04-01 | 2025-08-14 |
Showing 20 of 339. Sign in to see all of them.
Multiple Myeloma (20) · HIV Infections (15) · Helicobacter Infections (14) · Acquired Immunodeficiency Syndrome (12) · Gastritis (12) · Mycobacterium avium-intracellulare Infection (12) · Dyspepsia (11) · Peptic Ulcer (9) · Infections (8) · Community-Acquired Pneumonia (7) · Lymphoma, B-Cell, Marginal Zone (7) · Pneumonia (7) · Stomach Neoplasms (7) · Lymphoma (6) · AIDS-Related Opportunistic Infections (5)
Kaohsiung Veterans General Hospital. (10) · Xijing Hospital of Digestive Diseases (9) · Abbott (8) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · Shandong University (7) · Weill Medical College of Cornell University (7) · Shanghai Jiao Tong University School of Medicine (6) · Takeda (6) · Hellenic Institute for the Study of Sepsis (5) · National Taiwan University Hospital (5) · Ranbaxy Laboratories Limited (5) · Eli Lilly and Company (4) · Samsung Medical Center (4) · Alexandria University (3) · Boehringer Ingelheim (3)
United States (75) · China (50) · Taiwan (29) · South Korea (25) · Egypt (13) · Greece (9) · Pakistan (9) · United Kingdom (9) · Canada (8) · Denmark (7) · Italy (7) · Japan (7) · Belgium (6) · France (6) · Hong Kong (6)
Ping-I Hsu, Bachelor (6) · Xiuli Zuo, MD,PhD (5) · Hong Lu, M.D. (4) · Yongquan Shi, Ph. D (4) · Eric Sicard, M.D. (3) · Ruben Niesvizky, MD (3) · Tai-cherng Liou, MD (3) · Benson CA (2) · Bin Cheng, Doctor (2) · David Y Graham, MD (2) · Feng-Woei Tsay, Bachelor (2)
PMID 26935876, PMID 31111585, PMID 32545856, PMID 33197289, PMID 10086658, PMID 10887619, PMID 10933646, PMID 11197288, PMID 11895791, PMID 15276398, PMID 15470330, PMID 15840453, PMID 15907550, PMID 16174856, PMID 16339220, PMID 16437639, PMID 16441468, PMID 16611267, PMID 17067919, PMID 17292768, PMID 17466292, PMID 17608775, PMID 1771934, PMID 17989313, PMID 18237386, PMID 18444850, PMID 19036078, PMID 19298337, PMID 19477891, PMID 19588358, PMID 19920766, PMID 20610825, PMID 20616418, PMID 20920764, PMID 20947881, PMID 21108561, PMID 21188333, PMID 21345487, PMID 21447948, PMID 21480191, PMID 21482566, PMID 21482570, PMID 21923713, PMID 22288485, PMID 22530208, PMID 22564837, PMID 23158886, PMID 23299315, PMID 23357290, PMID 23520311
2014 (4), 2009 (2), 2023 (2), 2018 (1), 2019 (1), 2025 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), R01GM063666 (1), R01NS099535 (1), R01NS111280 (1), U10HL074073 (1), U10HL074204 (1), U10HL074206 (1)